ReviewInternational journal of molecular sciences2018
Eradicating Suicide at Its Roots: Preclinical Bases and Clinical Evidence of the Efficacy of Ketamine in the Treatment of Suicidal Behaviors.
Review in International journal of molecular sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 85 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
85 citing papers in PubMed, 1 synthesis or guideline pooled it, 167 citations in OpenAlex.
- Ketamine for substance use disorders: a systematic review and meta-analysis.Frontiers in psychiatry · 2026Pooled it
- Baseline Plasma BDNF Levelsare Associated with Antianhedonic Effects of Repeated-Dose Intravenous Ketamine in Major Depressive Disorder.Current neuropharmacology · 2023Trial
- The effect of single administration of intravenous ketamine augmentation on suicidal ideation in treatment-resistant unipolar depression: Results from a randomized double-blind study.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · 2021Trial
- Brixadi for Stimulant Use Disorder: Evolving Pharmacologic Considerations and Clinical Implications.Advances in therapy · 2026Review
- Review
- Navigating 'k-land': a qualitative exploration of participants' experiences of ketamine-assisted psychotherapy for methamphetamine use disorder.Frontiers in psychiatry · 2026Article
- Innovative Approaches to Depression Therapy: The Antidepressant Efficacy and Mechanisms of General Anesthetics.Current neuropharmacology · 2026Review
- The relationship between childhood trauma, early maladaptive schema and alexithymia: a multi-group path model of clinical and non-clinical samples.Frontiers in psychology · 2026Article
- HLA Class II Alleles and Suicidal Behavior: Evidence from a Case-Control Study.International journal of molecular sciences · 2025Article
- Defining Treatment-Resistant Bipolar Depression: Recommendations From the ISBD Task Force.Bipolar disorders · 2025Review
- Genome-wide methylome-based molecular pathologies associated with depression and suicide.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025Article
- The Meaning of Social Support for Mental Health Service-Users: The Case Managers' Perspective.Community mental health journal · 2025Article
- From trauma to depression: structural, synaptic, epigenetic, and molecular pathways linking early stress to lifelong vulnerability.Frontiers in psychiatry · 2025Review
- Genetics of suicide ideation. A role for inflammation and neuroplasticity?European archives of psychiatry and clinical neuroscience · 2024Article
- Abnormal Serum BDNF and p-mTOR in MDD in Adolescents with Childhood Trauma.Neuropsychiatric disease and treatment · 2024Article
- Esketamine for treatment‑resistant depression: A review of clinical evidence (Review).Experimental and therapeutic medicine · 2023Review
- How does IL-6 change after combined treatment in MDD patients? A systematic review.Brain, behavior, & immunity - health · 2023Review
- Adherence to, and Persistence of, Antidepressant Therapy in Patients with Major Depressive Disorder: Results from a Population-based Study in Italy.Current neuropharmacology · 2023Article
- Overcoming the myths of esketamine administration: different and not difficult.Frontiers in psychiatry · 2023Review
- Differences in the prevalence and clinical correlates of comorbid suicide attempts in patients with early- and late-onset major depressive disorder.Frontiers in psychiatry · 2023Article
25 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 10 institutions in 7 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the continuous advancement in neurosciences as well as in the knowledge of human behaviors pathophysiology, currently suicide represents a puzzling challenge. The World Health Organization (WHO) has established that one million people die by suicide every year, with the impressive daily rate of a suicide every 40 s. The weightiest concern about suicidal behavior is how difficult it is for healthcare professionals to predict. However, recent evidence in genomic studies has pointed out the essential role that genetics could play in influencing person's suicide risk. Combining genomic and clinical risk assessment approaches, some studies have identified a number of biomarkers for suicidal ideation, which are involved in neural connectivity, neural activity, mood, as well as in immune and inflammatory response, such as the mammalian target of rapamycin (mTOR) signaling. This interesting discovery provides the neurobiological bases for the use of drugs that impact these specific signaling pathways in the treatment of suicidality, such as ketamine. Ketamine, an
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.